Previous Close | 57.12 |
Open | 57.25 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 56.61 - 57.33 |
52 Week Range | 50.27 - 76.04 |
Volume | |
Avg. Volume | 1,735,168 |
Market Cap | 12.791B |
Beta (5Y Monthly) | 0.65 |
PE Ratio (TTM) | 21.50 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for INCY
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
(Bloomberg) -- A lawyer for the US Securities and Exchange Commission told a jury that a former biotech executive’s $120,000 windfall on a trade in a competing company’s stock was “like betting on a game when you know who’s going to win” because he knew the pending takeover of his firm would likely boost its rival.Most Read from BloombergTrump’s Net Worth Hits $6.5 Billion, Making Him One of World’s 500 Richest PeopleBiden Gains Ground Against Trump in Six Key States, Poll ShowsTrump Vows to Pay
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]